Hansa Biopharma Posts 135% Revenue Surge, Files FDA Application for Imlifidase

Event summary

  • Q4 2025 revenue hit 76.0 MSEK, up 135% YoY, driven by IDEFIRIX sales growth.
  • Submitted BLA for imlifidase in kidney transplantation; FDA review underway.
  • Raised 671.5 MSEK (~$71.3M) via directed share issue.
  • Full-year 2025 IDEFIRIX sales reached 204.7 MSEK, up 46% YoY.
  • Plans FDA interactions for HNSA-5487 in Guillain-Barré syndrome in H1 2026.

The big picture

Hansa Biopharma's strong financial performance underscores growing demand for IDEFIRIX in European kidney transplantation markets. The BLA submission for imlifidase marks a critical step toward U.S. expansion, while the company's strategic pivot to next-generation therapies like HNSA-5487 reflects broader industry trends in immunomodulation. Success hinges on regulatory approvals and commercial execution in high-growth therapeutic areas.

What we're watching

Regulatory Timing
Whether FDA grants Priority Review for imlifidase, potentially accelerating approval to August 2026.
Commercial Execution
The pace at which Hansa can scale IDEFIRIX adoption beyond Europe into the U.S. market.
Pipeline Progress
How HNSA-5487 development advances in Guillain-Barré syndrome following FDA interactions in H1 2026.